# Co-Diagnostics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Co-Diagnostics, Inc.). ## Overview Co-Diagnostics, Inc. develops and commercializes molecular diagnostic technologies and tests, with a focus on PCR-based platforms used to detect infectious diseases and other targets. The company also appears to support commercialization through licensing, distribution, and related diagnostic product activities rather than a broad consumables or hospital-equipment model. ## Products & services • PCR-based molecular diagnostic tests • Diagnostic assay development and commercialization • CoPrimer-based molecular detection technology • Test kit licensing and distribution arrangements • General financial advisory-related equity issuance support - **Molecular diagnostic tests** (60%) — PCR and other molecular assays used to detect infectious diseases and other biological targets. - **Diagnostic technology platform** (20%) — Proprietary CoPrimer technology and related assay design capabilities that underpin test performance. - **Licensing and commercialization** (15%) — Licensing, distribution, and partner-led commercialization of diagnostic products and technologies. - **Other corporate activities** (5%) — Ancillary corporate and financing-related activities that support the business. - PCR-based molecular diagnostic tests - Diagnostic assay development and commercialization - CoPrimer-based molecular detection technology - Test kit licensing and distribution arrangements - General financial advisory-related equity issuance support ## Customers Customers are primarily laboratories, healthcare providers, distributors, and commercial partners that need molecular testing capability for infectious disease detection. The company may also sell or license through channel partners in markets where local commercialization and regulatory access are important. Demand is driven by the need for accurate, scalable, and relatively fast diagnostic results. - **Clinical laboratories** (primary) — Buy PCR-based assays and test kits to run diagnostic workflows for infectious disease detection. - **Distributors and channel partners** (primary) — Purchase or license products to commercialize them in local markets where the company lacks direct reach. - **Healthcare providers** (secondary) — Use diagnostic tests to support patient care, triage, and treatment decisions. - **Commercial licensing partners** (secondary) — License technology or assays to expand product availability and monetize the platform. - **Public health and screening customers** (emerging) — Use molecular tests for surveillance, outbreak response, or high-volume screening. - Clinical laboratories buying molecular tests for routine diagnostics - Healthcare providers needing infectious disease testing capability - Distributors and channel partners commercializing tests locally - Commercial partners licensing technology or assays for market access - Public-health and screening users needing scalable PCR testing ## Geography The company is based in the United States, but the available excerpts do not disclose a country-by-country revenue split or operating footprint. Its business model suggests exposure to international commercialization through distributors and partners, which can make market access, regulatory approvals, and local demand conditions important. Because no authoritative geographic revenue table was provided, the geography breakdown is left empty. - Headquartered in the United States - No country-level revenue disclosure was provided in the excerpts - Likely relies on partner-led international commercialization - Regulatory access and local distribution matter for market expansion - Geographic mix cannot be quantified from the provided filings ## Strategy The company’s strategy appears centered on advancing its molecular diagnostic platform and expanding commercialization through partners, licensing, and selective market access. Recent filings also show capital-market activity, including an equity distribution agreement and advisory-share issuance, indicating a focus on funding development and expansion. Preserving liquidity while building product adoption is likely central to execution. - **Commercialize diagnostic products through partners** (short-term) — Partner-led distribution can extend reach without requiring a large direct-sales footprint. - **Fund development and expansion** (short-term) — The company states it expects to use available funds to finance future development and expansion. - **Strengthen diagnostic platform differentiation** (medium-term) — Proprietary assay design technology can support product performance and licensing value. - Advance molecular diagnostic technology and assay portfolio - Expand commercialization through distributors and partners - Use licensing to broaden market reach without heavy direct sales - Maintain liquidity through equity and advisory financing tools - Support future development and expansion with available funds ## Risks Co-Diagnostics faces the typical risks of a small molecular diagnostics company: commercialization uncertainty, regulatory dependence, and competition from larger diagnostic platforms. The filings also show ongoing financing reliance, which can dilute shareholders and signal that operating cash generation may be limited. Because the company depends on product adoption and partner execution, delays in market uptake or reimbursement can materially affect results. - **Commercialization and adoption risk** [high] — Revenue depends on customers and partners adopting the company’s molecular tests and technology. - **Financing dilution risk** [high] — The company has used equity-based financing and advisory-share issuance, which can dilute existing holders. - **Regulatory and reimbursement risk** [high] — Diagnostic products often require approvals, clearances, and payer acceptance before scaling. - **Competitive pressure** [medium] — The molecular diagnostics market includes larger, better-capitalized competitors with broader menus. - Commercial adoption risk if tests do not gain broad market traction - Financing and dilution risk from equity issuance and capital needs - Regulatory and market-access risk in diagnostic commercialization - Competition from larger diagnostics companies and alternative platforms - Dependence on partners and distributors for market execution ## Accounting The most important accounting issue visible in the excerpts is equity-based financing, including the issuance of 500,000 shares for advisory services, which affects dilution and non-cash compensation expense. Investors should also watch revenue recognition for diagnostic product sales, licensing, and partner arrangements, since timing can differ depending on delivery, acceptance, or contract terms. As a smaller reporting company, the company may disclose fewer risk-factor details, so judgmental estimates and financing-related accounting deserve close attention. - **Share-based and equity-settled advisory compensation** — Affects operating expenses, dilution, and equity balances - **Revenue recognition for diagnostics and licensing** — Affects quarterly revenue timing and comparability - **Going-concern and liquidity assessment** — Affects disclosure, financing assumptions, and valuation - Equity issuance for advisory services creates dilution and non-cash expense - Revenue recognition may vary across product sales, licensing, and partner deals - Contract terms can affect timing of revenue and receivables - Smaller reporting company status limits some risk-factor disclosure - Capital-raising transactions can affect share count and per-share metrics --- *Last updated: 2026-04-28T19:58:25.532809+00:00*